Korro Bio, Inc.
NASDAQ:KRROBiotechnology
+$1.76 today
- Market cap
- $169.10M
- Beta
- 2.10
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$9.79
Volume 0.16M
Average 0.15M
KRRO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Korro Bio, Inc.NASDAQ: KRRO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$20.06M, compared with -$23.8M a year earlier. Trailing-twelve-month EBITDA was -$78.15M.
Context
- EBITDA amounted to 1299.5% of revenue in FY2025, down 2590.7 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -$42.52M (+48.8%) for the fiscal year ending Dec 2026, a step up from the +6.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$20.06M-31.7% QoQ
- Last fiscal yearDec 2025
- -$83.06M+6.0% YoY
- LTMMar 2026
- -$78.15M+14.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +15.7% | +9.4% | -6.4 pp |
| 1 year | +6.0% | +48.8% | +42.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (83.06M) USD
- Year-over-year change
- +6.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (83.06M) | +6.0% |
| FY2024 | 2024-12-31 | (88.35M) | -9.2% |
| FY2023 | 2023-12-31 | (80.9M) | -43.2% |
| FY2022 | 2022-12-31 | (56.49M) | +29.4% |
| FY2021 | 2021-12-31 | (80.07M) | — |
EBITDA vs competitors
How KRRO compares with its peers on the latest reported figures
- KRRO's LTM Mar 2026 EBITDA of -$78.15M is the 5th highest of the 11 companies compared; the peer median is -$99.72M.
- Its year-over-year change of +14.5% is the 2nd highest of 9, against a peer median of -18.1%.
- EBITDA amounts to 2034.0% of revenue for KRRO, versus a peer median of 8478.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$5.14M | +92.4% | — | 2.4% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$39.05M | — | — | — |
| LTM Mar 2026 | -$71.29M | -16.9% | — | — | |
| LTM Mar 2026 | -$78.13M | — | — | 8478.5% | |
| LTM Mar 2026 | -$78.15M | +14.5% | — | 2034.0% | |
| LTM Mar 2026 | -$88.27M | +2.7% | — | 245200.0% | |
| LTM Mar 2026 | -$111.17M | -19.0% | — | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | -$125.94M | -65.1% | — | — |
| LTM Mar 2026 | -$159.48M | -49.1% | — | — | |
| LTM Mar 2026 | -$165.68M | -74.6% | — | — | |
| LTM Mar 2026 | -$193.41M | -17.1% | — | — | |
| Peer median (excluding KRRO) | -$99.72M | -18.1% | — | 8478.5% | |
Competitors are the stored peer set for KRRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 14.07M | 0 | 0 | 2.27M | 6.39M |
| Cost of Revenue | 3.84M | 0 | 0 | 0 | 4.28M |
| Gross Profit | 10.23M | 0 | 0 | 2.27M | 2.11M |
| Gross Margin | 72.7% | — | — | 100.0% | 33.0% |
| Research & Development | 59.32M | 42.2M | 57.25M | 63.64M | 65.58M |
| Selling, General & Admin | 34.93M | 16.8M | 36.54M | 30.55M | 28.16M |
| Operating Expenses | 94.26M | 59M | 84.53M | 94.18M | 89.45M |
| Depreciation & Amortization | 3.84M | 2.51M | 3.63M | 3.57M | 4.28M |
| EBITDA | (80.07M) | (56.49M) | (80.9M) | (88.35M) | (83.06M) |
| EBITDA Margin | -569.1% | — | — | -3890.1% | -1299.5% |
| Operating Income | (84.03M) | (59M) | (84.53M) | (91.91M) | (87.34M) |
| Operating Margin | -597.3% | — | — | -4047.1% | -1366.4% |
| Interest Income | 397K | 947K | 0 | 0 | 0 |
| Interest Expense | 764K | 118K | 0 | 0 | 0 |
| Other Income / Expenses | (640K) | 976K | 3.39M | 8.47M | (29.28M) |
| Income Before Tax | (84.67M) | (58.02M) | (81.15M) | (83.44M) | (116.62M) |
| Pre-Tax Margin | -601.9% | — | — | -3674.2% | -1824.5% |
| Income Tax Expense | 15K | 10K | 27K | 141K | 637K |
| Net Income | (84.69M) | (58.03M) | (81.17M) | (83.58M) | (117.26M) |
| Net Margin | -602.0% | — | — | -3680.4% | -1834.5% |
| EPS (Basic) | (4.94) | (227.58) | (53.09) | (9.37) | (12.48) |
| EPS (Diluted) | (4.94) | (227.42) | (53.08) | (9.37) | (12.48) |
| Weighted Avg Shares | 4.45M | 255K | 1.53M | 8.92M | 9.4M |
| Weighted Avg Shares (Diluted) | 4.45M | 255.17K | 1.53M | 8.92M | 9.4M |
Korro Bio, Inc.
NASDAQ:KRRO
Intrinsic Alpha fair value
Locked
Current Price
$12.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.